Cocrystal Pharma, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K covers the Annual Meeting of Shareholders held on July 28, 2016. The filing details the results of shareholder votes on director elections, a reverse stock split, and the ratification of the independent auditor. The report was signed on July 29, 2016, by Gary Wilcox, Interim Chief Executive Officer.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance events and voting results.
Material Changes and Voting Results
- Director Elections: Six nominees were elected to the Board of Directors, each receiving over 99% of the votes cast. Notably, former CEO Jeffrey Meckler resigned prior to the meeting and was not elected; the Board has not yet appointed a replacement for the vacancy.
- Reverse Stock Split: Shareholders approved a reverse stock split. The 1-for-5 ratio received the highest number of votes (497,241,467), followed by the 1-for-12 ratio (464,152,623) and a range between 1-for-5 and 1-for-12 (464,648,891). All options received a majority of votes.
- Auditor Ratification: BDO USA, LLP was ratified as the independent registered public accounting firm for fiscal year 2015 with over 99% of votes cast in favor.
Guidance, Outlook, and Risks
The filing does not contain financial guidance, future outlook, or specific risk factors. The primary contingency noted is the vacancy on the Board of Directors following the resignation of Jeffrey Meckler, which remains unfilled at the time of this report.
Investor Verification Checklist
- Verify the specific reverse stock split ratio the Board intends to implement, as multiple ratios received majority support.
- Monitor for the appointment of a new director to fill the vacancy left by Jeffrey Meckler.
- Review the definitive proxy materials filed on June 17, 2016, for detailed context on the proposals.